Rhythm Biosciences Launches Enhanced GeneType Colorectal Cancer Test

Rhythm Biosciences Ltd has officially launched its enhanced geneType TM Colorectal Cancer (CRC) Risk Assessment clinical test, marking a significant step in personalized cancer risk prediction. This updated test, which integrates additional clinical and lifestyle risk factors with the established 140-SNP polygenic risk score (PRS), aims to improve predictive accuracy for colorectal cancer across both genders and a wider age range.

The new version of the geneType TM CRC test is designed to facilitate earlier detection of individuals at heightened risk for colorectal cancer. By identifying those who might benefit from targeted screening, the test complements Rhythm’s existing ColoSTAT® blood-based CRC detection test. The recent validation data for the updated model was published in the peer-reviewed journal PLOS ONE, showcasing its enhanced predictive performance compared to traditional assessment methods.

Significant research indicates that nearly 50% of colorectal cancer cases can be prevented through lifestyle changes. By incorporating these risk factors into the geneType TM CRC test, Rhythm Biosciences aims to reach a broader population of at-risk individuals, promoting earlier interventions and continuous monitoring.

Key Applications of the Enhanced Test

The enhanced geneType TM CRC Risk Assessment test has multiple important applications. In Australia, for instance, compliance with recommended bowel cancer screening programs is currently below 50%. Individuals identified as higher risk through this test may be candidates for closer clinical monitoring, which could include colonoscopy, Faecal Immunochemical Testing (FIT), or the use of Rhythm’s ColoSTAT® test.

Dr. Erika Spaeth, Director of Clinical Affairs at Rhythm, highlighted the significance of this advancement: “The enhanced geneType TM CRC test strengthens our ability to identify individuals at elevated risk earlier, supporting more targeted screening and complementing ColoSTAT’s® role in colorectal cancer detection.”

About Rhythm Biosciences

Founded in 2017 and headquartered in Melbourne, Australia, Rhythm Biosciences Ltd is dedicated to transforming cancer diagnostics through innovative, affordable blood tests that facilitate early detection. The company is committed to improving patient outcomes by detecting cancers at their earliest stages, ultimately aiming to reduce the global burden of cancer and save lives. Rhythm Biosciences actively collaborates with global partners to commercialize and distribute these pioneering solutions.

For more information about their products and initiatives, visit their website at rhythmbio.com and follow the company on LinkedIn and X.